Literature DB >> 29904425

Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.

Jing Wang1, Yuan-Yuan Qi1, Xue-Ping Chen1, Li Ma1, Li-Li Zhang1, Yu Zhao1, Mei Wang2.   

Abstract

The present study aimed to investigate risk factors for renal recurrence in patients with type IV lupus nephritis (LN). Univariate and multivariate analyses were conducted to using the Cox proportional hazard model and the Kaplan-Meier method. A total 244 patients were diagnosed with type IV LN; 100 (28.49%) relapsed and 144 (41.03%) recovered successfully. Kaplan-Meier method analysis indicated that patients with type IV LN affecting the digestive tract had high renal recurrence rates. Patients with hyperglobulinemia, positive anti-ribonucleoprotein and anti-Sjögren's syndrome type B (anti-SSB) antibodies, thrombus in the loop or non-inflammatory necrotizing vasculopathy also had a high recurrence rate. Furthermore, patients achieving partial remission had an increased recurrence rate compared with patients achieving complete remission. Patients undergoing maintenance treatment with glucocorticoids alone had a higher recurrence rate compared with patients who used alternative treatment schemes. Univariate and multivariate regression analyses by the Cox proportional hazard model determined that the effect of systemic lupus erythematosus in the gastrointestinal tract, increased serum globulin levels and positive anti-SSB antibody at onset were risk factors for the recurrence of LN type IV. The present study demonstrated that clinical risk factors of renal recurrence in patients with LN type IV include LN in the gastrointestinal tract, increased serum globulin levels, positive anti-SSB antibodies at onset and the use of glucocorticoid-only maintenance treatment.

Entities:  

Keywords:  lupus nephritis; renal flare; risk factors

Year:  2018        PMID: 29904425      PMCID: PMC5996681          DOI: 10.3892/etm.2018.6130

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 2.  Hydroxychloroquine in systemic lupus erythematosus (SLE).

Authors:  C Ponticelli; G Moroni
Journal:  Expert Opin Drug Saf       Date:  2016-12-14       Impact factor: 4.250

3.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

Review 4.  Systemic lupus erythematosus.

Authors:  Larissa Lisnevskaia; Grainne Murphy; David Isenberg
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

Review 5.  Lupus Nephritis in Asia: Clinical Features and Management.

Authors:  Desmond Y H Yap; Tak Mao Chan
Journal:  Kidney Dis (Basel)       Date:  2015-08-05

6.  A surge in anti-dsDNA titer predicts a severe lupus flare within six months.

Authors:  N Pan; I Amigues; S Lyman; R Duculan; F Aziz; M K Crow; K A Kirou
Journal:  Lupus       Date:  2013-12-06       Impact factor: 2.911

7.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

8.  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.

Authors:  G S Alarcón; J Calvo-Alén; G McGwin; A G Uribe; S M A Toloza; J M Roseman; M Fernández; B J Fessler; L M Vilá; C Ahn; F K Tan; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

9.  Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy.

Authors:  S-J Moon; H S Park; S-K Kwok; J H Ju; B S Choi; K-S Park; J-K Min; H-Y Kim; S-H Park
Journal:  Lupus       Date:  2013-02-19       Impact factor: 2.911

10.  Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus.

Authors:  I E Coremans; P E Spronk; H Bootsma; M R Daha; E A van der Voort; L Kater; F C Breedveld; C G Kallenberg
Journal:  Am J Kidney Dis       Date:  1995-10       Impact factor: 8.860

View more
  1 in total

1.  Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis.

Authors:  Ruping Hong; Dong Xu; Evelyn Hsieh; Yirong Xiang; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Front Med (Lausanne)       Date:  2020-11-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.